Abstract P294 Figure 1 Kaplan-Meier estimates of time to clinically significant event (decline from baseline FEV₁ of ≥ 100 mL; increase from baseline of ≥ 4 units SGRQ total score; severe exacerbation; death) in patients with GOLD stage B COPD

clinically significant events in patients with GOLD stage B COPD.

Methods A total of 5162 patients were randomised to O 5 µg, T 2.5 µg, T 5 µg, T/O 2.5/5 µg or T/O 5/5 µg (delivered via Respimat[®] inhaler) in two 52-week, parallel-group, double-blind studies (NCT01431274; NCT01431287). In this *post hoc* analysis of the combined TONADO[®] data, clinical deterioration was defined according to a composite end point: time to first decrease in trough forced expiratory volume in 1 second (FEV₁) from baseline of ≥ 100 mL; increase in St George's Respiratory Questionnaire (SGRQ) total score from baseline of ≥ 4 units; severe (hospitalised) exacerbation; or death. Only patients classified as GOLD stage B were included. Data are presented for comparisons of the licensed doses of T 5 µg and T/O 5/5 µg.

Results 306 and 310 patients were included in this analysis in the T 5 µg and T/O 5/5 µg treatment groups, respectively. Time to clinical deterioration was significantly longer with T/O 5/5 µg than T 5 µg (25th percentile 128 versus 85 days; HR 0.650; 95% CI: 0.524, 0.805; $p < 0.0001$) (Figure). Times to trough FEV₁ decline and SGRQ increase were significantly longer with T/O 5/5 µg than T 5 µg (226 versus 91 days and 369 versus 175 days, respectively). 25th percentiles for time to severe exacerbation and time to death were not estimable due to low event rates.

Conclusions In the TONADO[®] studies, T/O increased time to clinical deterioration compared to T alone in patients with GOLD stage B disease. This suggests that, in this patient population, T/O is more effective than T in preventing these significant

events. Further studies are warranted to prospectively study this effect.

Funding Boehringer Ingelheim.

Please refer to page A272 for declarations of interest in relation to abstract P294.

P295 EFFICACY AND SAFETY OF TIOTROPIUM/OLODATEROL IN PATIENTS WITH COPD BY ATS CATEGORY

¹F Maltais, ²E Pizzichini, ³L Grönke, ³F Voß, ⁴E Derom. ¹Département de Médecine, Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada; ²Department of Pulmonology, NUPAIVA (Asthma Research Centre), Universidade Federal de Santa Catarina, Santa Catarina, Brazil; ³Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, Germany; ⁴Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium

10.1136/thoraxjnl-2016-209333.438

Rationale The once-daily combination of tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β_2 -agonist, has demonstrated efficacy and safety in chronic obstructive pulmonary disease (COPD).¹ Recently, it has been demonstrated that patients with milder disease (GOLD 2) have better bronchodilator responses compared to those with more severe disease. This *post hoc* analysis investigated whether the response to T/O and to T alone is influenced by forced expiratory volume in 1 second (FEV₁) American Thoracic Society (ATS) category (mild, moderate or severe).

Abstract P295 Table 1 Lung-function responses at 24 weeks according to baseline ATS category

Trough FEV ₁ , L			FEV ₁ AUC ₀₋₃ , L	
µg	n	Adjusted mean (SE)	n	Adjusted mean (SE)
Mild	351	0.058 (0.011)	353	0.152 (0.011)
T 5	338	0.141 (0.012)*	340	0.275 (0.011)*
T/O 5/5				
Moderate	320	0.097 (0.011)	322	0.174 (0.011)
T 5	338	0.156 (0.011)**	339	0.282 (0.011)*
T/O 5/5				
Severe	347	0.088 (0.009)	351	0.131 (0.009)
T 5	341	0.123 (0.009)***	344	0.227 (0.009)*
T/O 5/5				

*p<0.0001 vs T 5 µg; **p<0.001 vs T 5 µg; ***p<0.01 vs T 5 µg
SE, standard error

Methods In total, 5162 patients were randomised to O 5 µg, T 2.5 µg, T 5 µg, T/O 2.5/5 µg or T/O 5/5 µg (via Respimat[®] inhaler) in two 52-week, parallel-group, double-blind studies (TONADO[®] 1 and 2: NCT01431274; NCT01431287). This *post hoc* analysis focuses on the T 5 µg and T/O 5/5 µg analyses. Primary efficacy end points were trough FEV₁ response (ie, change from baseline) and FEV₁ area under the curve from 0–3 hours (AUC₀₋₃) response. Data are presented for patients by ATS category subgroups: mild (predicted FEV₁ ≥50%), moderate (35 ≤ 50%) and severe (<35%), using data pooled from both of the TONADO[®] studies.

Results In all disease-severity categories, the improvements in trough FEV₁ and FEV₁ AUC₀₋₃ were larger with T/O compared to T alone. However, trough FEV₁ and FEV₁ AUC₀₋₃ responses were generally greater in patients with mild (T/O versus T: both p < 0.0001) or moderate (T/O versus T: p < 0.001 and p < 0.0001, respectively) COPD versus those with severe COPD (T/O versus T: p < 0.01 and p < 0.0001, respectively) at baseline (Table). Treatments were well tolerated across all ATS categories and similar responses were observed in both of the studies individually.

Conclusions These data build on the analysis of the GOLD 2 population from TONADO[®] and confirm that patients with mild to moderate disease derive greater benefits with T/O than with T. There was an overall trend towards greater lung-function improvement with T/O or T alone in patients with mild/moderate versus severe airflow obstruction.

Funding Boehringer Ingelheim.

REFERENCE

1 Buhl R, et al. *Eur Respir J* 2015;**45**:969–979.

Please refer to page A273 for declarations of interest in relation to abstract P295.

P296

EFFECT OF TIOTROPIUM/OLODATEROL THERAPY ON COPD EXACERBATIONS IN THE TONADO[®] STUDIES

¹E Derom, ²M Fležar, ³L Grönke, ³F Voß, ⁴R Buhl. ¹Ghent University Hospital, Ghent, Belgium; ²University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia; ³Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, Germany; ⁴Pulmonary Department, Mainz University Hospital, Mainz, Germany

10.1136/thoraxjnl-2016-209333.439

Rationale The lung-function efficacy, symptomatic benefits and safety of combined tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β₂-agonist, for the treatment of COPD, was established in the year-long TONADO[®] studies (NCT01431274; NCT01431287). It is unknown if these benefits of T/O translate into a reduction in COPD exacerbation rate.

Methods Two replicate, randomised, double-blind, parallel-group trials assessed T/O 2.5/5 µg and T/O 5/5 µg compared to the monocomponents T 5 µg, T 2.5 µg and O 5 µg (all delivered via Respimat[®] inhaler) in patients with moderate to very severe COPD. Primary end points included lung function (forced expiratory volume in 1 second [FEV₁] area under the curve from 0–3 hours response, trough FEV₁ response) and quality of life (SGRQ). Analysis of the number of exacerbations and time to exacerbation was pre-specified using data from the combined TONADO[®] studies. We present data from the T/O and T treatment arms.

Results 4124 patients were evaluable for the T/O and T treatment arms. Moderate or severe exacerbations occurred in 27.7% of patients with T/O 5/5 µg, 25.8% of patients with T/O 2.5/5 µg, 28.8% with T 5 µg and 29.6% with T 2.5 µg. Severe exacerbations occurred in 5.9% of patients receiving T/O 5/5 µg, 4.5% receiving T/O 2.5/5 µg, 4.5% receiving T 5 µg and 5.2% receiving T 2.5 µg. The treatment comparisons for any exacerbation and moderate/severe exacerbations were generally consistent between the two studies, except for a higher number of severe exacerbations with T/O 5/5 µg in TONADO[®] 1 only (Table).

Conclusions Although there were fewer exacerbations overall with T/O 2.5/5 µg or 5/5 µg compared to T 2.5 µg or 5 µg, and a numerically longer time to first moderate/severe exacerbation,

Abstract P296 Table 1 Treatment comparisons of time to first COPD exacerbation and first moderate/severe COPD exacerbation

Treatment comparison, µg	Time to first COPD exacerbation	Time to first moderate/severe COPD exacerbation	Time to first severe COPD exacerbation
T/O 5/5 –	0.938	0.931	1.279
T 5	(0.801, 1.099)	(0.791, 1.095)	(0.874, 1.871)
T/O 5/5 –	0.897	0.901	1.105
T 2.5	(0.767, 1.049)	(0.767, 1.059)	(0.766, 1.593)
T/O 2.5/5 –	0.819	0.822	0.817
T 2.5	(0.698, 0.960)*	(0.697, 0.969)*	(0.551, 1.210)
T/O 2.5/5 –	0.857	0.850	0.948
T 5	(0.730, 1.007)	(0.720, 1.003)	(0.632, 1.424)
T/O 5/5 –	1.095	1.096	1.352
T/O 2.5/5	(0.931, 1.288)	(0.927, 1.295)	(0.922, 1.983)

Hazard ratio (95% confidence interval) p<0.05